Crinetics Pharmaceuticals (CRNX) Accumulated Depreciation (2017 - 2025)

Crinetics Pharmaceuticals' Accumulated Depreciation history runs 9 years deep, the most recent figure standing at $9.6 million for Q2 2025.

• In Q2 2025, Accumulated Depreciation rose 53.84% year-over-year to $9.6 million; the TTM figure through Jun 2025 stood at $9.6 million (up 53.84% YoY), while the FY2024 annual figure was $7.7 million, up 52.57% from the prior year.
• Accumulated Depreciation for Q2 2025 stood at $9.6 million, up from $8.6 million in the prior quarter.
• The five-year high for Accumulated Depreciation was $9.6 million in Q2 2025, with the low at $3.0 million in Q1 2021.
• The 5-year median for Accumulated Depreciation is $4.6 million (2023), against an average of $5.2 million.
• The sharpest annual moves came in 2021 and 2023: Accumulated Depreciation soared 62.02% in 2021, then climbed 16.95% in 2023.
• Crinetics Pharmaceuticals' Accumulated Depreciation stood at $3.5 million in 2021, then rose by 17.36% to $4.1 million in 2022, then advanced by 24.09% to $5.1 million in 2023, then soared by 52.57% to $7.7 million in 2024, then advanced by 23.98% to $9.6 million in 2025.
• Business Quant data shows CRNX's Accumulated Depreciation at $9.6 million in Q2 2025, $8.6 million in Q1 2025, and $7.7 million in Q4 2024.